Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GIXKQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LA22-MMC
|
|||||
| Synonyms |
LA22/mitomycin conjugate (AbMax); LA22-MMC
Click to Show/Hide
|
|||||
| Organization |
Jingtiancheng Biotechnology (Beijing) Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Lung cancer [ICD11:2C25]
Investigative
Squamous skin carcinoma [ICD11:2C31]
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR mAb LA22
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Mitomycin C
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
|
Linker Info | ||||
| Conjugate Type |
The principle used to conjugate small molecule anti-cancer drug MMC to anti-EGFR mAb LA22 involved the activation of the amino group with SPDP, followed by disulfide exchange with iminothiolane-modified mAb LA22.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.